Results for: TMO

Thermo Fisher Scientific Inc. (NYSE: TMO) reported third-quarter revenue of $10.59 billion, narrowly missing analyst expectations. While revenue growth improved sequentially, it remained flat compared to the prior year. Despite the revenue miss, adjusted earnings per share beat estimates. The company reaffirmed its 2024 sales guidance and adjusted its EPS guidance slightly upward. TMO shares traded lower following the earnings report.

Thermo Fisher Scientific (TMO) continues to impress with its strategic partnerships and product launches, but macroeconomic challenges and declining COVID-19 testing demand pose hurdles to its growth. The company’s strong track record of earnings beats and its expansion into new markets suggest long-term potential, but investors should remain aware of the current economic climate.